stockrow
Friday 6 November 2026
Export IMA’s income statement to Excel — free account
ImageneBio, Inc.
ImageneBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $800,000.00, down 77.1% from fiscal 2024.
- Revenue
- −60.1%
- EPS
- +85.9%
- Free cash flow
- +23.8%
Quarter to June 2026, against a year earlier
4.11
0.06
−1.44%
Follow IMA
Alert me
ImageneBio, Inc. (IMA) P/E ratio
ImageneBio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2025 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| 15 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IBIO iBio, Inc. compare | n/m |
| HOWL Werewolf Therapeutics, Inc. compare | n/m |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | n/m |
| APLM Apollomics Inc. compare | n/m |
| PLRX Pliant Therapeutics, Inc. compare | n/m |
| IMA ImageneBio, Inc. | n/m |
| HYFT MindWalk Holdings Corp. compare | n/m |
| TIL Instil Bio, Inc. compare | n/m |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)